English | 简体中文 | 繁體中文 | 한국어
 All Press Releases
 Pharma & Biotech BioTech
Novotech and Endpoints Present "Evolution of Cell & Gene Therapy in China: The Case for Universal CAR-T"
Jul 18, 2022 16:00 HKT
TrialWire Technology Platform Announces Success-based Patient Recruitment Plan
Jul 18, 2022 15:00 HKT
TrialWire(TM) 技术平台宣布基于成功的患者招募计划
Jul 18, 2022 15:00 HKT
TrialWire(TM) 技術平台宣布基於成功的患者招募計劃
Jul 18, 2022 15:00 HKT
Malaysian Genomics Appoints New Chairman
Jul 15, 2022 14:10 HKT
노보텍 고객사 SK바이오사이언스, 스카이코비원(SKYCovione(TM)) 코로나19 백신 국내 승인
Jul 14, 2022 20:00 HKT
贝康医疗与海尔生物强强联合,构建辅助生殖低温保存解决方案
Jul 14, 2022 13:25 HKT
貝康醫療與海爾生物強強聯合,構建輔助生殖低溫保存解決方案
Jul 14, 2022 13:24 HKT
Basecare Medical and Haier Biomedical Join Forces to Build Cryopreservation Solutions for Assisted Reproduction
Jul 14, 2022 13:23 HKT
Novotech 客户 SK bioscience 在韩国获得 SKYCovione(TM) COVID-19 疫苗批准
Jul 14, 2022 08:00 HKT
Novotech 客戶 SK bioscience 在韓國獲得 SKYCovione(TM) COVID-19 疫苗批准
Jul 14, 2022 08:00 HKT
FDA Grants De Novo Marketing Authorization to Apollo Endosurgery for Apollo ESG and Apollo REVISE, New Endoscopic Systems for Patients with Obesity
Jul 13, 2022 19:30 HKT
Malaysian Genomics Forms Partnership for Expansion in Saudi Arabia
Jul 13, 2022 15:00 HKT
Novotech Client SK bioscience Achieves SKYCovione(TM) COVID-19 Vaccine Approval in Korea
Jul 13, 2022 14:30 HKT
SinoMab Received the Highest Subsidy from HKSTP
Jul 08, 2022 19:03 HKT
中国抗体获香港科学园最高专项补贴
Jul 08, 2022 19:01 HKT
中國抗體獲香港科學園最高專項補貼
Jul 08, 2022 19:00 HKT
Malaysian Genomics Proposes Private Placement
Jul 08, 2022 18:00 HKT
Co-led by Legend Capital, Huili Biotechnology Completes Series A Financing Round with Hundreds of Million RMB
Jul 07, 2022 19:13 HKT
Malaysian Genomics to Offer First-Ever Sports-Based Tests Specific to Southeast Asian Genetic Profiles
Jul 06, 2022 16:00 HKT
<< Previous  Next >>
Copyright © 2022 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: